£50m motor neurone disease funding 'offers glimmer of hope'
Campaigners including former policeman Chris Johnson hope a cure can be found in the next five years. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 15, 2021 Category: Consumer Health News Source Type: news

Motor Neurone Disease symptoms: 7 final stages signs
MOTOR NEURONE DISEASE is a rare life-limiting condition that rapidly progresses. Knowing what symptoms to expect is essential to improve the quality of life of those diagnosed with this tragic disease. (Source: Daily Express - Health)
Source: Daily Express - Health - November 14, 2021 Category: Consumer Health News Source Type: news

Lab-grown 'mini brains' are developed from the cells of dementia and motor neurone patients
Being able to grow small organ-like models of the brain allowed researchers from the University of Cambridge to understand what happens at the earliest stages of disease. (Source: the Mail online | Health)
Source: the Mail online | Health - October 21, 2021 Category: Consumer Health News Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential ben...
Source: Roche Media News - September 24, 2021 Category: Pharmaceuticals Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential ben...
Source: Roche Investor Update - September 24, 2021 Category: Pharmaceuticals Source Type: news

Let's cure MND: JRR Tolkien's great-grandson in plea after brother's death
THE GREAT-grandson of Lord Of The Rings author JRR Tolkien says that his family felt "alone, abandoned and ignored" as his late brother Mike battled motor neurone disease. Royd Tolkien nursed his brother daily for three years until his death in 2015, desperately hoping his care would help restore him. (Source: Daily Express - Health)
Source: Daily Express - Health - September 12, 2021 Category: Consumer Health News Source Type: news

Motor Neurone Disease: 'It's like having a death sentence hanging over your family...'
A FAMILY that has lost six members to an inherited form of motor neurone disease has called for the Government to do more to remove the "death sentence" hanging over them. Cris Hoskin says she felt helpless as her two sons died from MND as a result of a familial gene passed down through the male descendants of her grandfather, who had symptoms of the disease at a time when little was known about it. (Source: Daily Express - Health)
Source: Daily Express - Health - August 22, 2021 Category: Consumer Health News Source Type: news

Motor neurone disease: Brave Jo on the cruel illness that robbed her independence
After leaving university, Jo Knowlton focused on starting a career with the police force, as a "forensic imaging officer". (Source: Daily Express - Health)
Source: Daily Express - Health - August 14, 2021 Category: Consumer Health News Source Type: news

Motor neurone disease: Three early warning signs in the hands to look out for
MOTOR neurone disease is a rare condition that affects around two in every 100,000 people in the UK each year. There are about 5,000 people living with the condition in the UK at any one time. Muscle aches are a common complaint among those in the early stages of the condition, particularly in the hands. (Source: Daily Express - Health)
Source: Daily Express - Health - August 9, 2021 Category: Consumer Health News Source Type: news

Assisted dying: Campaigners renewed hope for change in the law
David Peace intends to travel abroad to end his life before his motor neurone disease deteriorates further. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 2, 2021 Category: Consumer Health News Source Type: news

Data for Roche ’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies aged 1-7 months old with symptomatic Type 1 spinal muscular atr ophy (SMA). The study met its primary endpoint with 29% of infants (12/41) sitting without support for at least five seconds* by month 12, a milestone not seen in the natural course of the disease. Safety for Evrysdi in the FIREFISH Part 2 study was consistent with its known safety profile.“With...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news

Data for Roche ’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies aged 1-7 months old with symptomatic Type 1 spinal muscular atr ophy (SMA). The study met its primary endpoint with 29% of infants (12/41) sitting without support for at least five seconds* by month 12, a milestone not seen in the natural course of the disease. Safety for Evrysdi in the FIREFISH Part 2 study was consistent with its known safety profile.“With...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news

Sunday Express MND campaign: Give us the funds so we CAN cure Motor Neurone Disease
THE Sunday Express is today launching a crusade calling for £50million of Government funding for a "game-changing" Motor Neurone Disease Research Institute. (Source: Daily Express - Health)
Source: Daily Express - Health - July 17, 2021 Category: Consumer Health News Source Type: news

OHIO professor awarded NIH grant to research the motor neuron in relation to aging
(Ohio University) The research will look at the role of the motor neuron, the final neuron that connects the nervous system with the muscle, in health and disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 30, 2021 Category: International Medicine & Public Health Source Type: news

Health: Exercise can increase the risk of motor neurone disease, scientists warn
Three large-scale genetic analyses involving people who undertake different habitual levels of exercise were conducted by experts from the University of Sheffield looking for links to motor neurone disease. (Source: the Mail online | Health)
Source: the Mail online | Health - June 11, 2021 Category: Consumer Health News Source Type: news

Scientists link intense exercise with MND risk in some people
Those with a certain genetic makeup more likely to develop motor neurone disease, study confirmsRegular strenuous exercise raises the risk of developing motor neurone disease (MND) in people who are genetically predisposed to the condition, researchers say.Scientists at the University of Sheffield found a causal relationship between high intensity physical activity and the disorder among those already susceptible to the disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 11, 2021 Category: Science Authors: Ian Sample Science editor Tags: Medical research Motor neurone disease Science Health University of Sheffield Education Source Type: news

Motor neurone disease: Intense exercise increases risk, say scientists
Regular and strenuous exercise can increase the risk of MND in people who are vulnerable, scientists say. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - June 10, 2021 Category: Consumer Health News Source Type: news

Discovering the Secrets of Motor Neurons with Single Cell Sequencing
Researchers identify new motor neuron subgroups and gain insights into amyotrophic lateral sclerosis (ALS). (Source: The Scientist)
Source: The Scientist - May 5, 2021 Category: Science Tags: Podcasts Source Type: news

Earswitch to allow people with MND to communicate again using hidden, tiny ear muscle
(University of Bath) The 'Earswitch', being developed by a GP and a team of researchers at the University of Bath, could offer fresh hope for people with conditions such as Motor Neurone Disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2021 Category: International Medicine & Public Health Source Type: news

Miniaturized models of neuron-muscle interactions give insight in ALS
(International Society for Stem Cell Research) Researchers have developed a new miniaturized model of neuromuscular junction formation that will have broad applications in studying motor neuron pathology and the discovery of potential therapeutics in ALS. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 22, 2021 Category: International Medicine & Public Health Source Type: news

Tipping Point: Woman has voice reconstructed thanks to ITV show appearance
Helen Whitelaw appeared on Tipping Point before Motor Neurone Disease rendered her speechless. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 15, 2021 Category: Consumer Health News Source Type: news

High cholesterol: The health condition has been linked to motor neurone disease
HIGH cholesterol may increase the likelihood of motor neurone disease - an incurable condition. Who is most at risk of developing the life-changing illness? And could statins protect against the malady? (Source: Daily Express - Health)
Source: Daily Express - Health - March 13, 2021 Category: Consumer Health News Source Type: news

Risdiplam Promising for Spinal Muscular Atrophy Risdiplam Promising for Spinal Muscular Atrophy
Infants with type 1 spinal muscular atrophy showed increased expression of functional survival motor neuron protein after 1 year of treatment in new FIREFISH findings.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 10, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Researchers reveal process behind harmful glial cell change in motor neurone disease
(The Francis Crick Institute) Scientists at the Francis Crick Institute and UCL have identified the trigger of a key cellular change in amyotrophic lateral sclerosis (ALS), a type of motor neurone disease. The findings could help develop new treatments for many neurological diseases with the same change, including Parkinson's and Alzheimer's. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 3, 2021 Category: Biology Source Type: news

Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi ™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. SMA is a leading genetic cause of death in infants and 5q SMA is the most common form of the disease . SMA causes progressive muscle weakness and atrophy, and significant unmet need remains, particularly in adults ...
Source: Roche Investor Update - February 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi ™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. SMA is a leading genetic cause of death in infants and 5q SMA is the most common form of the disease . SMA causes progressive muscle weakness and atrophy, and significant unmet need remains, particularly in adults ...
Source: Roche Media News - February 26, 2021 Category: Pharmaceuticals Source Type: news

Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
Basel, 25 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine has published Evrysdi ™ (risdiplam) data from the dose finding Part 1 of the pivotal FIREFISH study in infants with symptomatic Type 1 spinal muscular atrophy (SMA). The data show that treatment with Evrysdi at 12 months helped 90% (19/21) of these infants survive without permanent ventilation and 33% (7/21) sit withou t support for at least 5 seconds, which is not normally seen in the natural course of the disease. The study also found that treatment with Evrysdi increased the levels of survival of m...
Source: Roche Investor Update - February 25, 2021 Category: Pharmaceuticals Source Type: news

Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
Basel, 25 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine has published Evrysdi ™ (risdiplam) data from the dose finding Part 1 of the pivotal FIREFISH study in infants with symptomatic Type 1 spinal muscular atrophy (SMA). The data show that treatment with Evrysdi at 12 months helped 90% (19/21) of these infants survive without permanent ventilation and 33% (7/21) sit withou t support for at least 5 seconds, which is not normally seen in the natural course of the disease. The study also found that treatment with Evrysdi increased the levels of survival of m...
Source: Roche Media News - February 25, 2021 Category: Pharmaceuticals Source Type: news

Poor corticospinal motor neuron health is associated with increased symptom severity in the acute phase following repetitive mild TBI and predicts early ALS onset in genetically predisposed rodents - Alkaslasi MR, Cho NE, Dhillon NK, Shelest O, Haro-Lopez PS, Linaval NT, Ghoulian J, Yang AR, Vit JP, Avalos P, Ley EJ, Thomsen GM.
Traumatic brain injury (TBI) is a well-established risk factor for several neurodegenerative disorders including Alzheimer's disease and Parkinson's disease, however, a link between TBI and amyotrophic lateral sclerosis (ALS) has not been clearly elucidate... (Source: SafetyLit)
Source: SafetyLit - February 6, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Motor neurone disease: Edinburgh scientists reveal breakthrough
University of Edinburgh scientists are a step closer to being able to reverse the damage caused by MND. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - January 19, 2021 Category: Consumer Health News Source Type: news

Rob Burrow: Rugby League legend's year living with MND
The Rugby League legend looks back on a year of challenges since his motor neurone disease diagnosis. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 25, 2020 Category: Consumer Health News Source Type: news

Antiepileptic drug reduces motor neuron excitability in ALS
(Massachusetts General Hospital) The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital (MGH). In addition, the multi-site study involves the first clinical investigation of ALS using a drug identified through an induced pluripotent stem cell model. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 10, 2020 Category: International Medicine & Public Health Source Type: news

Motor Neurone Disease: Scientists find mutation that could end hell of disease
SCIENTISTS have identified a new genetic mutation that increases risk of motor neurone disease, raising hopes of better targeted treatments. (Source: Daily Express - Health)
Source: Daily Express - Health - December 2, 2020 Category: Consumer Health News Source Type: news

Trinity researchers discover how the brain 're-wires' after disease
(Trinity College Dublin) Trinity College researchers are studying how the brain re-wires itself in neurological disease. The team is building treatments for today's more common global conditions like Motor Neurone Disease (MND/ALS) and Spinal Muscular Atrophy and their findings could impact rehabilitation for patients, the discovery of effective drugs and quantifying the potential efficacy of new therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 24, 2020 Category: International Medicine & Public Health Source Type: news

ALS Ice Bucket Challenge Co-Founder Pat Quinn Dead At 37
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p16").init({"mcp":"cbs","width":"100%","height":"100%","video":"4895420","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p16","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","job...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 23, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Syndicated CBSN Boston ALS Ice Bucket Challenge Pat Quinn Pete Frates Source Type: news

Curing the incurable: teaching an old drug new tricks to fight ovarian cancer
The winning essay in the Max Perutz science writing award 2020 was written by Sarah Taylor from the MRC Institute of Genetics and Molecular Medicine at the University of EdinburghIn May, PhD students who are funded by the Medical Research Council (MRC) were invited to enter theMax Perutzscience writing award 2020 and to tell the general public “why your research matters”. From the many entries received, the 10that made the shortlist covered diverse topics, including motor neurone disease, self-harm, babies ’ experiences of pain, and bone loss resulting from space travel.The essays were judged by theObserv...
Source: Guardian Unlimited Science - October 18, 2020 Category: Science Authors: The Observer Tags: Science Medical research Cancer research Source Type: news

Occupational exposure to electric shocks and extremely low-frequency magnetic fields and motor neurone disease - Chen GX, Mannetje A, Douwes J, Berg LH, Pearce N, Kromhout H, Glass B, Brewer N, McLean DJ.
In a New Zealand population-based case-control study we assessed associations with occupational exposure to electric shocks, extremely low-frequency magnetic fields (ELF-MF) and motor neurone disease using job-exposure matrices to assess exposure. Particip... (Source: SafetyLit)
Source: SafetyLit - October 12, 2020 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

Evidence of Alzheimer's, Parkinson's & MND in brains of young people exposed to dirty air
(Lancaster University) After examining the brainstems of 186 young Mexico City residents aged between 11 months and 27 years of age, researchers, including Professor Barbara Maher from Lancaster University, found markers not only of Alzheimer's disease, but also of Parkinson's and of motor neurone disease (MND) too.These markers of disease were coupled with the presence of tiny, distinctive nanoparticles within the brainstem - their appearance and composition indicating they were likely to come from vehicle pollution. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 6, 2020 Category: International Medicine & Public Health Source Type: news

Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA)
Basel, 28 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi ™ (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy (SMA). The 2-year results in infants treated with the therapeutic dose of Evrysdi (17/21) showed that they continued to improve and achieve motor milestones. This exploratory analysis showed that an estimated 88% of infants were alive and required no permanent ventilation at two years. In addition, at two years, 59% (10/17 vs. 7/17 at 1-year) of infants were able to sit without support...
Source: Roche Investor Update - September 28, 2020 Category: Pharmaceuticals Source Type: news

Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA)
Basel, 28 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi ™ (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy (SMA). The 2-year results in infants treated with the therapeutic dose of Evrysdi (17/21) showed that they continued to improve and achieve motor milestones. This exploratory analysis showed that an estimated 88% of infants were alive and required no permanent ventilation at two years. In addition, at two years, 59% (10/17 vs. 7/17 at 1-year) of infants were able to sit without support...
Source: Roche Media News - September 28, 2020 Category: Pharmaceuticals Source Type: news

Scientists identify promising new ALS drug candidates
(University of Liverpool) Scientists have taken a significant step forward in the search to find effective new drug candidates for the treatment of Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2020 Category: International Medicine & Public Health Source Type: news

Peter: The Human Cyborg: Scientist diagnosed with motor neurone disease opens up about journey
Peter Scott-Morgan, 62, from Devon, who has motor neurone disease, appears in Channel 4's documentary Peter: The Human Cyborg tonight, as he uses technology to transform his life. (Source: the Mail online | Health)
Source: the Mail online | Health - August 26, 2020 Category: Consumer Health News Source Type: news

Coronavirus pandemic halts life-saving UK cancer and heart disease research
Thousands of clinical trials have closed permanently or been suspended – and may never have the cash to restartCoronavirus – latest updatesSee all our coronavirus coverageMore than 1,500 clinical trials of new drugs and treatments for cancers, heart disease and other serious illnesses have been permanently closed down in Britain in the wake of the Covid-19 pandemic. In addition, a further 9,000 have been suspended andmost will need major cash injections if they are to be reactivated.The figures highlight the catastrophic effect that Covid-19 has had on UK medical research, which has suffered a devastating blow ...
Source: Guardian Unlimited Science - August 22, 2020 Category: Science Authors: Robin McKie Science editor Tags: Medical research Cancer research Heart disease Motor neurone disease Coronavirus outbreak Infectious diseases Science UK news Health Society Source Type: news

Blood Test Identifies People With ALS Blood Test Identifies People With ALS
A panel of eight micro RNA can identify patients with amyotrophic lateral sclerosis/motor neuron disease, researchers report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 28, 2020 Category: Pathology Tags: Neurology & Neurosurgery News Source Type: news

HEALTH NOTES: Trial for motor neurone drug and why cycling could risk men's sex life
Bike sales have soared during lockdown. But men may want to think twice before donning Lycra and getting in the saddle, as research suggests it could put them at an increased risk of impotence. (Source: the Mail online | Health)
Source: the Mail online | Health - July 18, 2020 Category: Consumer Health News Source Type: news

Scientists link bowel inflammation to higher risk of dementia
Study is latest to find high degree of correlation between gut health and mental healthPeople living with inflammatory bowel disease (IBD) have more than twice the risk of developing dementia, researchers have revealed in the latest study to link gut health to neurological diseases.A growing body of research suggests changes in the gastrointestinal tract may affect the brain through two-way communication known as the gut-brain axis.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 24, 2020 Category: Science Authors: Nicola Davis Tags: Dementia Alzheimer's Health Parkinson's disease Mental health Motor neurone disease Society Digestive disorders Source Type: news

Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA)
Basel, 12 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented two-year data from Part 1 of its pivotal SUNFISH trial in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA) at the virtual Cure SMA Annual Conference, 8-12 June, 2020. The results of an exploratory efficacy analysis show risdiplam significantly improved motor function after 24 months of treatment compared to natural history data. In addition, preliminary 12 month data from JEWELFISH, a trial in people with all types of SMA aged 6 months to 60 years previously treated with other SMA therapies, showed that treatment with risdiplam le...
Source: Roche Media News - June 12, 2020 Category: Pharmaceuticals Source Type: news

Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA)
Basel, 12 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented two-year data from Part 1 of its pivotal SUNFISH trial in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA) at the virtual Cure SMA Annual Conference, 8-12 June, 2020. The results of an exploratory efficacy analysis show risdiplam significantly improved motor function after 24 months of treatment compared to natural history data. In addition, preliminary 12 month data from JEWELFISH, a trial in people with all types of SMA aged 6 months to 60 years previously treated with other SMA therapies, showed that treatment with risdiplam le...
Source: Roche Investor Update - June 12, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA)
Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1 – 7 months old with symptomatic Type 1 spinal muscular atrophy (SMA). The study met its primary endpoint with 29% of infants (12/41; p
Source: Roche Media News - April 28, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA)
Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1 – 7 months old with symptomatic Type 1 spinal muscular atrophy (SMA). The study met its primary endpoint with 29% of infants (12/41; p
Source: Roche Investor Update - April 28, 2020 Category: Pharmaceuticals Source Type: news